Article summary
Dr Goeken joined Lobe Sciences on 20 October 2026, bringing more than 20 years of clinical development, regulatory strategy and medical affairs experience. He will oversee work on L-130, a psilocin-based candidate for generalized anxiety disorder, including a planned US IND submission, and S-100, an oral lipid formulation for sickle cell disease being advanced towards Phase 3.
Continue to the original publication for the complete article.